Lawrenceville-based biopharmaceutical company Celsion Corporation announced Wednesday that it has received commitments from investors to purchase approximately $15 million in common stock in an at-the-market registered direct offering led by a dedicated health care fund.
According to the announcement, Celsion entered into definitive purchase agreements with the investors to sell 3.6 million shares of common stock at a per-share price of $4.16. The closing of the offering is expected to take place around January 21.
The estimated net profit to the company from the offering are expected to be approximately $13.8 million. The announcement said H.C. Wainwright & Co., LLC acted as exclusive placement agent in connection with the offering, Celsion said in a statement.
Like us on Facebook: facebook.com/NJBIZ